An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...

Atrogi AB, a clinical stage biotech company pioneering novel GPCR pathway-signalling modulators to transform metabolic and muscle health, today announces that the first subjects have been dosed in a ...

A team from Atrogi AB has reported the activity of ATR-127, a novel dual adrenergic agonist targeting β2- and β3-adrenoceptors (ARs), for the potential treatment of steatohepatitis, obesity and ...

A new class of beta blockers designed to activate only when struck by specific wavelengths of light could allow doctors to ...

The popularity of GLP-1-based drugs is testament to the importance of a drug that increases fat burning and lowers blood sugar. Now, a drug—taken in the form of a tablet—offers the outcome of ...

Rendering a drug effective or ineffective in a flash at the appropriate location—this is the focus of research in ...

Atrogi has dosed the first participants in a human study of its lead candidate ATR‑258, marking a significant step forward ...

First-in-class oral therapy ATR-258 mimics the effects of exercise - driving fat loss, increasing muscle, and improving metabolism - with broad potential as a novel treatment for muscle-sparing ...